Pharma Times
NOVEMBER 25, 2021
A team of scientists and pharmaceutical collaborators have discovered a ‘bench to bedside’ drug design, which will hopefully improve the future treatment of Alzheimer’s disease.
pharmaphorum
NOVEMBER 25, 2021
A new variant of COVID-19 identified in Botswana with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines. The B.1.1.529 variant has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date, although it’s not yet clear if it is more or less transmissible.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
NOVEMBER 25, 2021
A new clinical trial of heterologous â or âmix-and-matchâ â combinations of COVID-19 vaccines is set to start in Pakistan: seeking to add to research on the effectiveness of such combinations.
Drug Patent Watch
NOVEMBER 26, 2021
Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
NOVEMBER 24, 2021
With the latest approval from the EC, patients in Europe suffering from metastatic triple-negative breast cancer can now receive Gilead Science’s Trodlevy as part of their treatment.
pharmaphorum
NOVEMBER 23, 2021
Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for whole genome sequencing (WGS) has reached a level at which its national rollout on the NHS may someday become a reality. The timing of this announcement is particularly opportune, as increasing knowledge and advances in WGS amongst scientists has resulted in the technology becoming increasingly affordable and effective, making its incorporation into the existing standardis
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
NOVEMBER 23, 2021
This is the first jury verdict in an opioid case. The decision embraced a key legal argument that judges in other opioid cases had recently rejected.
Pharma Times
NOVEMBER 23, 2021
NICE has published draft guidance recommending risdiplam (Evrysdi) as part of a managed access agreement (MAA) for the treatment of the rare genetic disorder spinal muscular atrophy (SMA).
pharmaphorum
NOVEMBER 25, 2021
Health insurance is not enough to provide the necessary affordable access to care for the US’ most vulnerable, finds new PhRMA report. For too many Americans, insurance coverage is not providing the health security it’s meant to. The Pharmaceutical Research and Manufacturers of America’s (PhRMA) first Patient Experience Survey (PES) has found that three in ten people with medical insurance still face financial barriers to accessing healthcare and prescription medicines.
Outsourcing Pharma
NOVEMBER 23, 2021
The alliance is aimed at expanding service to pharmaceutical firms and other partners, and advancing treatment options for patients across North America.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NY Times
NOVEMBER 23, 2021
This is the first jury verdict in an opioids case. The decision embraced a key legal argument that judges in other opioids cases had recently rejected.
Pharma Times
NOVEMBER 26, 2021
The Food and Drug Administration (FDA) granted approval for emergency use of the Comirnaty vaccine in children in October 2021.
pharmaphorum
NOVEMBER 22, 2021
Skip Rizzo, PhD, research director for medical virtual reality at the University of Southern California’s Institute for Creative Technologies (USC ICT), tells us how its virtual reality (VR) therapy BRAVEMIND is changing PTSD treatment and how pharma can leverage clinical VR. “There’s a strong evidence base for VR applications in many areas, but it’s also breaking down barriers to care.
Outsourcing Pharma
NOVEMBER 22, 2021
The StudyTeam Diversity Reporting feature is intended to aid sites and sponsors measure their efforts to reach patients from underrepresented communities.
NY Times
NOVEMBER 22, 2021
Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many cases were asymptomatic.
Pharma Times
NOVEMBER 25, 2021
The use of molnupiravir in COVID-19 cases aims to reduce the pressure on hospitals, in turn reducing the risk of patients developing more severe symptoms of the virus.
pharmaphorum
NOVEMBER 23, 2021
After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, said to be the biggest science lab of its kind in the UK. The Discovery Centre (DISC) based in the Cambridge Biomedical Campus – first given the green light in 2015 – is being officially opened today by Prince Charles. It can accommodate more than 2,200 research scientists, has 19,000 square metres of lab space, and boasts “the most advanced robotics, high-throughput scre
Drug Channels
NOVEMBER 23, 2021
Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.
NY Times
NOVEMBER 23, 2021
In her most substantial day of testimony, Ms. Holmes, the founder of the failed blood testing start-up Theranos, painted herself as someone whose best intentions were misinterpreted.
Pharma Times
NOVEMBER 24, 2021
The leading UK preganancy and baby loss charity Tommy’s have said with the approval of the hormonal drug, as many as 8,450 miscarrages a year could be prevented.
pharmaphorum
NOVEMBER 24, 2021
Takeda has scored the first-ever FDA approval of a treatment for refractory cytomegalovirus (CMV) infections in organ transplant patients, which can lead to an increased risk of complications and even death. Livtencity (maribavir) has been cleared for use in transplant patients aged 12 or over with CMV infections that do not respond to first-line treatment with current antiviral drugs for CMV, such as ganciclovir, valganciclovir, foscarnet and cidofovir.
Drug Channels
NOVEMBER 23, 2021
Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.
Outsourcing Pharma
NOVEMBER 23, 2021
Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies.
Pharma Times
NOVEMBER 26, 2021
Data from the UK’s Health Security Agency (UKHSA) has revealed that COVID-19 vaccines are safe in pregnancy.
pharmaphorum
NOVEMBER 23, 2021
Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. The French drugmaker has been enticed by an artificial intelligence (AI) algorithm developed by Chinese tech giant Baidu, which controls most of China’s search engine traffic and is sometimes referred to as the country’s Google.
Drug Channels
NOVEMBER 23, 2021
Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S.
Drug Patent Watch
NOVEMBER 26, 2021
Annual Drug Patent Expirations for TWYNEO Twyneo is a drug marketed by Sol-gel Technologies and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Sol-gel Technologies drug TWYNEO appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 23, 2021
Nykode Therapeutics, a clinical-stage biopharmaceutical company, announced that it has entered into a collaboration agreement with Regeneron.
pharmaphorum
NOVEMBER 25, 2021
Healthcare professional (HCP) engagement experienced significant shifts during the acute phase of the pandemic, as COVID-19 forced a rethink of traditional pharmaceutical sales and marketing practices, including the digitisation of events. With medical conferences and events long a mainstay for pharma-HCP interactions, the pandemic’s travel restrictions, and lockdowns forced these in-person meet-ups to go virtual.
Drug Channels
NOVEMBER 22, 2021
Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review.
Drug Patent Watch
NOVEMBER 26, 2021
Annual Drug Patent Expirations for CALDOLOR Caldolor is a drug marketed by Cumberland Pharms and is included in one NDA. It is available from one supplier. There are ten patents…. The post New patent expiration for Cumberland Pharms drug CALDOLOR appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
NOVEMBER 26, 2021
After hosting a virtual ceremony in 2020, this year’s awards returned to the Royal Lancaster London hotel
pharmaphorum
NOVEMBER 26, 2021
Turkey could have its own COVID-19 vaccine Turkovac available for use by the end of the year, according to the country’s Health Minister Fahrettin Koca. An emergency use authorisation (EUA) application for the inactivated SARS-CoV-2 vaccine has been submitted to the Turkish Medicines and Medical Devices Agency (TITCK) on the back of preliminary data from ongoing phase 3 trials.
Pharma Mirror
NOVEMBER 26, 2021
In recent years, it has become more and more important to both consumers and investors that they support organisations which display a high level of social and environmental responsibility. This means that it’s no longer enough for businesses to manage their bottom lines and maintain profitability, they must also be conscious of the impact they have on the world around them.
Drug Patent Watch
NOVEMBER 25, 2021
Annual Drug Patent Expirations for CHILDREN%27S+ALLEGRA+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com. The post New patent expiration for Sanofi Aventis drug CHILDREN’S ALLEGRA ALLERGY appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
156 
Let's personalize your content